Last $14.74 USD
Change Today +0.63 / 4.46%
Volume 348.7K
VNDA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 4:30 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Richard W. Dugan

Director and Chairman of Audit Committee, Vanda Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 13 board members in 2 different organizations across 2 different industries.

See Board Relationships
72$127,099

Background*

Mr. Richard W. Dugan served as a Partner of Ernst & Young LLP, from 1976 to September 2002. Mr. Dugan served in a variety of managing and senior partner positions at Ernst & Young LLP, including Mid-Atlantic Area Senior Partner from 2001 to 2002, Mid-Atlantic Area Managing Partner from 1989 to 2001 and Pittsburgh Office Managing Partner from 1981 to 1989. He retired from Ernst & Young LLP in September 2002. Mr. Dugan has been a Director at Vanda Pharmaceuticals, Inc. ...

Read Full Background

Corporate Headquarters*

2200 Pennsylvania Avenue NW
Washington, District Of Columbia 20037

United States

Phone: 202-734-3400
Fax: 202-296-1450

Board Members Memberships*

Former Director
2003-2010
Former Director, Chairman of Audit Committee and Member of Compensation Committee
2004-N/A
Former Lead Independent Director, Chairman of Audit Committee and Member of Nominating & Corporate Governance Committee
2005-N/A
Former Director
2005-Present
Director and Chairman of Audit Committee

Education*

BSBA
Pennsylvania State University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

Exercisable Options108,073
Unexercisable Options7,501
Total Number of Options115,574

Total Compensation*

Total Annual Cash Compensation$54,949
Total Calculated Compensation$127,099
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $14.74 USD +0.63

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Lechleiter Ph.D.Chairman, Chief Executive Officer and President
Eli Lilly and Company
$1.5M
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.0M GBP
Christopher A. Viehbacher Chief Executive Officer, Director and Member of Strategy Committee
Sanofi
€3.0M
Masayo Tada Chief Executive Officer, President, Representative Director and Chairman of Risk Management Committee
Sumitomo Dainippon Pharma Co., Ltd.
--
Glenn A. Oclassen Sr.Chairman of the Board, Chief Executive Officer and President
Transcept Pharmaceuticals, Inc.
$560.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.